Antimicrobial therapeutics delivery systems based on biodegradable polylactide/polylactide-co-glycolide particles
- 87 Downloads
Infectious diseases are globally associated with high mortality in spite of the availability of therapeutic agents against most pathogenic microorganisms. This is due to the emergence of new infectious diseases and novel pathogen strategies to evade host defenses. There is thus a need to develop potent therapeutics and techniques for effective delivery of vaccines and drugs. Particles based on poly(lactic acid) and poly(lactic-co-glycolic acid) polymer-based particles are suitable delivery systems due to their biodegradable and biocompatible nature. They can be tailored to display various properties such as sustained release, dose sparing, bioactivity maintenance and targeted delivery. This review focuses on polymeric particle-based delivery systems to develop novel vaccines or drugs. Cellular interactions of particulate systems and the mechanism of action in animal models are also discussed.
KeywordsInfectious diseases Therapeutic agents Biodegradable polymer Polymeric particle Delivery system
The authors are grateful to the National Institute of Immunology for financial support.
Robin Kumar and Divya Jha have an equal contribution to this work, and all authors read and approved the final manuscript.
Compliance with ethical standards
Conflict of interests
The authors declare that they have no conflict of interests.
- Agallou M, Margaroni M, Athanasiou E, Toubanaki DK, Kontonikola K, Karidi K, Kammona O, Kiparissides C, Karagouni E (2017) Identification of BALB/c immune markers correlated with a partial protection to leishmania infantum after vaccination with a rationally designed multi-epitope cysteine protease a peptide-based nanovaccine. PLoS Negl Trop Dis 11(1):e0005311. https://doi.org/10.1371/journal.pntd.0005311 CrossRefGoogle Scholar
- Aldrian G, Vaissière A, Konate K, Seisel Q, Vivès E, Fernandez F, Viguier V, Genevois C, Couillaud F, Démèné H (2017) PEGylation rate influences peptide-based nanoparticles mediated siRNA delivery in vitro and in vivo. J Controll Release 256:79–91. https://doi.org/10.1016/j.jconrel.2017.04.012 CrossRefGoogle Scholar
- Allahyari M, Mohabati R, Amiri S, Rastaghi ARE, Babaie J, Mahdavi M, Vatanara A, Golkar M (2016) Synergistic effect of rSAG1 and rGRA2 antigens formulated in PLGA microspheres in eliciting immune protection against Toxoplasama gondii. Exp Parasitol 170:236–246. https://doi.org/10.1016/j.exppara.2016.09.008 CrossRefGoogle Scholar
- Bruno C, Agnolon V, Berti F, Bufali S, O’Hagan DT, Baudner BC (2016) The preparation and characterization of PLG nanoparticles with an entrapped synthetic TLR7 agonist and their preclinical evaluation as adjuvant for an adsorbed DTaP vaccine. Eur J Pharm Biopharm 105:1–8. https://doi.org/10.1016/j.ejpb.2016.05.013 CrossRefGoogle Scholar
- Carreño JM, Perez-Shibayama C, Gil-Cruz C, Printz A, Pastelin R, Isibasi A, Chariatte D, Tanoue Y, Lopez-Macias C, Gander B (2016) PLGA-microencapsulation protects Salmonella typhi outer membrane proteins from acidic degradation and increases their mucosal immunogenicity. Vaccine 34(35):4263–4269. https://doi.org/10.1016/j.vaccine.2016.05.036 CrossRefGoogle Scholar
- Chong CS, Cao M, Wong WW, Fischer KP, Addison WR, Kwon GS, Tyrrell DL, Samuel J (2005) Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. J Controll Release 102(1):85–99. https://doi.org/10.1016/j.jconrel.2004.09.014 CrossRefGoogle Scholar
- Cruz J, Flórez J, Torres R, Urquiza M, Gutiérrez J, Guzmán F, Ortiz C (2017) Antimicrobial activity of a new synthetic peptide loaded in polylactic acid or poly (lactic-co-glycolic) acid nanoparticles against Pseudomonas aeruginosa, Escherichia coli O157: H7 and methicillin resistant Staphylococcus aureus (MRSA). Nanotechnology 28(13):135102. https://doi.org/10.1088/1361-6528/aa5f63 CrossRefGoogle Scholar
- Dhakal S, Hiremath J, Bondra K, Lakshmanappa YS, Shyu D-L, Ouyang K, K-i Kang, Binjawadagi B, Goodman J, Tabynov K (2017) Biodegradable nanoparticle delivery of inactivated swine influenza virus vaccine provides heterologous cell-mediated immune response in pigs. J Controll Release 247:194–205. https://doi.org/10.1016/j.jconrel.2016.12.039 CrossRefGoogle Scholar
- Genta I, Colonna C, Conti B, Caliceti P, Salmaso S, Speziale P, Pietrocola G, Chiesa E, Modena T, Dorati R (2016) CNA-loaded PLGA nanoparticles improve humoral response against S. aureus-mediated infections in a mouse model: subcutaneous vs. nasal administration strategy. J Microencapsul 33(8):750–762CrossRefGoogle Scholar
- Hiremath J, K-i Kang, Xia M, Elaish M, Binjawadagi B, Ouyang K, Dhakal S, Arcos J, Torrelles JB, Jiang X (2016) Entrapment of H1N1 influenza virus derived conserved peptides in PLGA nanoparticles enhances T cell response and vaccine efficacy in pigs. PLoS ONE 11(4):e0151922. https://doi.org/10.1371/journal.pone.0151922 CrossRefGoogle Scholar
- Kasturi SP, Kozlowski PA, Nakaya HI, Burger MC, Russo P, Pham M, Kovalenkov Y, Silveira EL, Havenar-Daughton C, Burton SL (2017) Adjuvanting a simian immunodeficiency virus vaccine with toll-like receptor ligands encapsulated in nanoparticles induces persistent antibody responses and enhanced protection in TRIM5α restrictive macaques. J Virol 91(4):e01844. https://doi.org/10.1128/JVI.01844-16 CrossRefGoogle Scholar
- Li P, Asokanathan C, Liu F, Khaing KK, Kmiec D, Wei X, Song B, Xing D, Kong D (2016) PLGA nano/micro particles encapsulated with pertussis toxoid (PTd) enhances Th1/Th17 immune response in a murine model. Int J Pharm 513(1):183–190. https://doi.org/10.1016/j.ijpharm.2016.08.059 CrossRefGoogle Scholar
- Liu L, Ma P, Wang H, Zhang C, Sun H, Wang C, Song C, Leng X, Kong D, Ma G (2016) Immune responses to vaccines delivered by encapsulation into and/or adsorption onto cationic lipid-PLGA hybrid nanoparticles. J Controll Release 225:230–239. https://doi.org/10.1016/j.jconrel.2016.01.050 CrossRefGoogle Scholar
- Marasini N, Khalil ZG, Giddam AK, Ghaffar KA, Hussein WM, Capon RJ, Batzloff MR, Good MF, Skwarczynski M, Toth I (2016) Lipid core peptide/poly (lactic-co-glycolic acid) as a highly potent intranasal vaccine delivery system against Group A streptococcus. Int J Pharm 513(1):410–420. https://doi.org/10.1016/j.ijpharm.2016.09.057 CrossRefGoogle Scholar
- Margaroni M, Agallou M, Kontonikola K, Karidi K, Kammona O, Kiparissides C, Gaitanaki C, Karagouni E (2016) PLGA nanoparticles modified with a TNFα mimicking peptide, soluble Leishmania antigens and MPLA induce T cell priming in vitro via dendritic cell functional differentiation. Eur J Pharm Biopharm 105:18–31. https://doi.org/10.1016/j.ejpb.2016.05.018 CrossRefGoogle Scholar
- Metz SW, Tian S, Hoekstra G, Yi X, Stone M, Horvath K, Miley MJ, DeSimone J, Luft CJ, de Silva AM (2016) Precisely molded nanoparticle displaying DENV-E proteins induces robust serotype-specific neutralizing antibody responses. PLoS Negl Trop Dis 10(10):e0005071. https://doi.org/10.1371/journal.pntd.0005071 CrossRefGoogle Scholar
- Pandey SK, Patel DK, Maurya AK, Thakur R, Mishra DP, Vinayak M, Haldar C, Maiti P (2016) Controlled release of drug and better bioavailability using poly (lactic acid-co-glycolic acid) nanoparticles. Int J Biol Macromol 89:99–110. https://doi.org/10.1016/j.ijbiomac.2016.04.065 CrossRefGoogle Scholar
- Peyre M, Audran R, Estevez F, Corradin G, Gander B, Sesardic D, Johansen P (2004) Childhood and malaria vaccines combined in biodegradable microspheres produce immunity with synergistic interactions. J Controll Release 99(3):345–355. https://doi.org/10.1016/j.jconrel.2004.07.014 CrossRefGoogle Scholar
- Sahin A, Esendagli G, Yerlikaya F, Caban-Toktas S, Yoyen-Ermis D, Horzum U, Aktas Y, Khan M, Couvreur P, Capan Y (2017) A small variation in average particle size of PLGA nanoparticles prepared by nanoprecipitation leads to considerable change in nanoparticles’ characteristics and efficacy of intracellular delivery. Artif Cells Nanomed Biotechnol 45:1657. https://doi.org/10.1080/21691401.2016.1276924 CrossRefGoogle Scholar
- Watkins HC, Pagan CL, Childs HR, Posada S, Chau A, Rios J, Guarino C, DeLisa MP, Whittaker GR, Putnam D (2017) A single dose and long lasting vaccine against pandemic influenza through the controlled release of a heterospecies tandem M2 sequence embedded within detoxified bacterial outer membrane vesicles. Vaccine 35:5373. https://doi.org/10.1016/j.vaccine.2017.08.013 CrossRefGoogle Scholar
- Zhang N-Z, Xu Y, Wang M, Chen J, Huang S-Y, Gao Q, Zhu X-Q (2016) Vaccination with Toxoplasma gondii calcium-dependent protein kinase 6 and rhoptry protein 18 encapsulated in poly (lactide-co-glycolide) microspheres induces long-term protective immunity in mice. BMC Infect Dis 16(1):168. https://doi.org/10.1186/s12879-016-1496-0 CrossRefGoogle Scholar